THE IMPACT OF ANTI-DIABETIC DRUGS IN CARDIOVASCULAR OUTCOMES
Keywords:
Cardiovascular mortality, Cardiovascular prevention, Diabetes mellitus
Abstract
In most developed countries, Cardiovascular diseases (CVD) remain the main cause of morbidity and mortality in the general population, especially among the elderly.1 People with Diabetes mellitus (DM) are on average at double the risk of CVD.2 Cardiovascular disease (CVD) prevention includes all the actions intended to eliminate or reduce the impact of these disorders and their disabilities in the population or even targeted at individuals. The goal of this editorial is to review the pharmacological strategies aimed to control blood glucose that was proven to be useful in preventing death related to CVD or other important cardiovascular outcomes (i.e. myocardial infarction, stroke or renal impairment).
Downloads
Download data is not yet available.
References
1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano A. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J 2016;37(29):2315-2381
2. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease:
a collaborative meta-analysis of 102 prospective studies. Lancet2010; 375:2215-2222.
3. UKPDS Study Group. "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK
Prospective Diabetes Study (UKPDS) Group." Lancet 1998. 352(9131):854-865.
4. Homan RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 15:1577-1589
5. Saenz A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2005; (3): CD002966
6. Hong J, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;
36(5):1304-1311
7. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications on patients with adult onset diabetes: Vevaluation of phenformin therapy. Diabetes 1975; 24(suppl 1):65-184.
8. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232-242
9. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326.
10. Margulies KB, Anstrom KJ, Redfield MM, et al. A randomized trial of Liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). American Heart Association 2015 Scientific Sessions; November 8, 2015/ Orlando, Florida. Abstract 20102.
11. Johannes FE, Mann MD, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 Diabetes. N Engl J Med 2017; 377:839-848.
12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE,Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin,
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 2117–2128.
13. Neal B, Perkovic V, Mahaffey K et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 2017: 1-14.
14. Kosiborod M, et al. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other GlucoseLowering Drugs: The CVD-REAL Study.
Circulation 2017, 1-117.
15. Kernan W, Viscoli C, Furie L, Young S. Pioglitazone after Ischmic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 1321-1331.
16. Writing group for the DCCT/Edic Research Group: Orchand TJ, Nathan DM, Zinman B, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015; 313:45-53
2. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease:
a collaborative meta-analysis of 102 prospective studies. Lancet2010; 375:2215-2222.
3. UKPDS Study Group. "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK
Prospective Diabetes Study (UKPDS) Group." Lancet 1998. 352(9131):854-865.
4. Homan RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 15:1577-1589
5. Saenz A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2005; (3): CD002966
6. Hong J, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;
36(5):1304-1311
7. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications on patients with adult onset diabetes: Vevaluation of phenformin therapy. Diabetes 1975; 24(suppl 1):65-184.
8. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232-242
9. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369:1317-1326.
10. Margulies KB, Anstrom KJ, Redfield MM, et al. A randomized trial of Liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). American Heart Association 2015 Scientific Sessions; November 8, 2015/ Orlando, Florida. Abstract 20102.
11. Johannes FE, Mann MD, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 Diabetes. N Engl J Med 2017; 377:839-848.
12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE,Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin,
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 2117–2128.
13. Neal B, Perkovic V, Mahaffey K et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes N Engl J Med 2017: 1-14.
14. Kosiborod M, et al. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other GlucoseLowering Drugs: The CVD-REAL Study.
Circulation 2017, 1-117.
15. Kernan W, Viscoli C, Furie L, Young S. Pioglitazone after Ischmic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 1321-1331.
16. Writing group for the DCCT/Edic Research Group: Orchand TJ, Nathan DM, Zinman B, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015; 313:45-53
How to Cite
1.
João Lucas O’Connell, Gabriela Carolina Borges. THE IMPACT OF ANTI-DIABETIC DRUGS IN CARDIOVASCULAR OUTCOMES. Med. res. chronicles [Internet]. 2017Oct.31 [cited 2024Dec.22];4(05):518-21. Available from: https://medrech.com/index.php/medrech/article/view/269
Section
Case Study
